At Rejuve Therapeutics, we believe aging is not only the accumulation of molecular damage, but also the progressive failure of coordinated gene regulatory programs that maintain cellular function and resilience.
Our mission is to halt and reverse biological aging at its roots by selectively activating intrinsic rejuvenation networks. Through systems biology and AI-guided gene network engineering, we aim to develop clinically actionable rejuvenation therapies that cure age-related diseases, extend healthspan, and redefine the boundaries of human vitality.
We envision a future where aging is not an inevitable decline but a treatable, reversible biological program.
A future where:
By merging genetic science, stem cell biology, and AI-powered discovery, Rejuve Therapeutics is building the foundation for the world’s first true rejuvenation medicine—a new class of therapies designed to restore youth at the source, cell by cell, tissue by tissue, and system by system.
Rejuve Therapeutics is a biotechnology company pioneering the next generation of gene-driven rejuvenation therapies. Our work began with the belief: cellular rejuvenation and dedifferentiation—long believed to be inseparable during reprogramming—can in fact be decoupled.
By specifically inhibiting the dedifferentiation pathway during the reprogramming process on our proprietary rejuvenation screening platform, we successfully achieved the demonstration of gene-mediated rejuvenation that preserves native cell identity, successfully reversing aging in human arterial endothelial cells without triggering pluripotency or tumor-associated risks. Our long-term aim is to develop simplified, clinically actionable rejuvenation gene cocktails.
Building upon this foundation, we are constructing the first Longitudinal Human Aging and Rejuvenation Gene Expression Atlas, enabling high-resolution mapping of the molecular events that drive aging and its reversal.
We are now actively collaborating with leading AI scientists to launch the next stage of our platform—leveraging advanced AI methodologies such as Dynamic Graph Modeling, as well as transfer learning to adapt state-of-the-art scRNA-seq foundation models for aging and rejuvenation. These efforts will enable AI-guided gene perturbation analysis and support our pursuit of simplified, clinically actionable rejuvenation gene cocktails.
Rejuve Therapeutics achieved a landmark scientific breakthrough: rejuvenating human endothelial cells while preserving their identity by specifically inhibiting the dedifferentiation pathway during the reprogramming process. Our (reprogramming + inhibiting dedifferentiation) gene-cocktails reverse senescence, restore youthful gene expression, and restart the cell cycle—without triggering dedifferentiation or pluripotency.
This is the first experimentally verified demonstration of gene-driven rejuvenation that avoids the risks associated with reprogramming. Our long-term aim is to develop simplified, clinically actionable rejuvenation gene cocktails
Aging is a dynamic, multi-step process—but until now, no system existed to map it comprehensively. Rejuve is building the first time-resolved molecular atlas capturing the full trajectories of aging, rejuvenation under different perturbation condations, differentiation, and reprogramming within the same human cell type.
With daily single-cell sequencing along four biological pathways within the same human cell type, this atlas provides unprecedented clarity into the genetic circuits that govern both aging and cellular youth.
With our Longitudinal Human Aging & Rejuvenation Atlas, we are now actively collaborating with leading AI scientists to launch the next stage of our platform—leveraging advanced AI methodologies such as Dynamic Graph Modeling, as well as transfer learning to adapt state-of-the-art single-cell foundation models, and transform them into specialized rejuvenation models uniquely optimized for aging biology. These approaches would enable in silico gene perturbation, discovery of causal rejuvenation regulators, and computational screening of trillions of gene combinations. This AI-driven discovery engine would dramatically accelerates our path toward a minimal, safe, and clinically translatable rejuvenation gene cocktail capable of reversing aging with unprecedented precision.
Dr. Gordon Ma is a geneticist, stem cell biologist, and biotech founder with over 20 years of experience in epigenetics, gene regulation, and rejuvenation biology. His PhD work produced the first evidence of CDH1 promoter methylation in precancerous tissue—a foundational contribution to modern epigenetics. He completed postdoctoral training at Harvard Medical School and the University of Colorado, where he studied XIST-mediated epigenetic regulation.
At the NIH (NHLBI), Dr. Ma conducted research in embryonic stem cell differentiation and cardiovascular regenerative biology and made key findings on mitochondrial regulation of pluripotency. He later founded several life science companies while continuing NIH research as a special volunteer for nearly a decade.
As Founder and CEO of Rejuve Therapeutics, Dr. Ma is the principal inventor of a patented method demonstrating gene-driven rejuvenation without dedifferentiation. His ongoing work includes large-scale single-cell sequencing studies and the development of the first Longitudinal Human Aging and Rejuvenation Gene Expression Atlas. He is collaborating closely with AI scientists on transfer learning and biological foundation models to identify key regulatory genes driving aging and rejuvenation and to develop clinically viable rejuvenation gene cocktails